![5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103) | Journal of Medicinal Chemistry 5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103) | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm900945d/asset/images/medium/jm-2009-00945d_0002.gif)
5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103) | Journal of Medicinal Chemistry
![133909-99-6 | N-Trityl Losartan | 2-Butyl-4-chloro-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol; Trityllosartan; Losartan EP Impurity H; Losartan LK1 | C₄₁H₃₇ClN₆O | TRC 133909-99-6 | N-Trityl Losartan | 2-Butyl-4-chloro-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol; Trityllosartan; Losartan EP Impurity H; Losartan LK1 | C₄₁H₃₇ClN₆O | TRC](https://www.trc-canada.com/prod-img/T888820.png)
133909-99-6 | N-Trityl Losartan | 2-Butyl-4-chloro-1-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl-4-yl]methyl]-1H-imidazole-5-methanol; Trityllosartan; Losartan EP Impurity H; Losartan LK1 | C₄₁H₃₇ClN₆O | TRC
Developing a highly validated and sensitive HPLC method for simultaneous estimation of losartan and spironolactone in tablets an
![Molecules | Free Full-Text | Preparation of Losartan Potassium Controlled Release Matrices and In-Vitro Investigation Using Rate Controlling Agents Molecules | Free Full-Text | Preparation of Losartan Potassium Controlled Release Matrices and In-Vitro Investigation Using Rate Controlling Agents](https://www.mdpi.com/molecules/molecules-27-00864/article_deploy/html/images/molecules-27-00864-g001.png)